spacer
home > epc > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS
European Pharmaceutical Contractor

New Approaches to Developing Cancer Drugs

The latest statistics make alarming reading: in the developed world one in three people will suffer from cancer and one in four will die from the disease. Due to an ageing population the worldwide incidence of cancer is predicted to double from 10 to 20 million by 2020 (WHO). Traditional approaches to cancer treatment rely on a combination of surgery, radiotherapy and chemotherapy. Current cancer drugs, which are mostly lethal for cells (cytotoxic), either affect DNA synthesis and the process of cell division or they react chemically with DNA to cause chromosomal damage.

These drugs have major limitations as they damage all proliferating cells and therefore produce considerable side effects. Drug resistance is another serious problem. Hence there is a major unmet need for more systematic but innovative and effective therapies for cancer treatment, especially for targeting early stages of the disease or later stage metastatic disease.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Gijsbertus J Pronk PhD, Senior Director, US Business Development at atugen AG

Gijsbertus J Pronk, PhD, is Senior Director in charge of US business development for atugen AG, Germany. Bert joined atugen, USA Inc in 2000 as Director of Research having formerly been Senior Scientist for Target Development with Chiron Corporation. Previously he held various research posts including a post-doctoral assignment in the laboratory of Dr Lewis T Williams at the Cardio-Vascular Research Institute (CVRI) at UC-San Francisco, where he studied programmed cell death (apoptosis).

spacer
Gijsbertus J Pronk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite

Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement